Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier

(2018) Janice K. Laramy et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

(2018) Minjee Kim et al.   MOLECULAR CANCER THERAPEUTICS

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

(2018) Minjee Kim et al.   PHARMACEUTICAL RESEARCH

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

(2017) Jann N Sarkaria et al.   NEURO-ONCOLOGY

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer

(2014) Adrian G. Sacher et al.   CANCER

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

Development and Evaluation of a Novel Microemulsion Formulation of Elacridar to Improve its Bioavailability

(2013) Ramola Sane et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study

(2013) D. H. Pafundi et al.   NEURO-ONCOLOGY

Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up

(2012) Sagar Agarwal et al.   CURRENT PHARMACEUTICAL DESIGN

Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein

(2012) Ishrat Jabeen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

(2011) Sagar Agarwal et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

(2011) Yasuo Uchida et al.   JOURNAL OF NEUROCHEMISTRY

Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

(2010) P. R. Lockman et al.   CLINICAL CANCER RESEARCH

Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

(2010) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Improved Measurement of Drug Exposure in the Brain Using Drug-Specific Correction for Residual Blood

(2009) Markus Fridén et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid

(2008) X. Liu et al.   DRUG METABOLISM AND DISPOSITION

Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein Binding

(2008) Nigel J. Waters et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE